Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20853467 | 0.95 | BCHE (0.34) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL1277218 | 0.81 | GPR119 (0.33) | BCHEGPR119MEN1KMT2ANR1H2 | |
| SCHEMBL7528678 | 0.77 | ESR2 (0.40) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL11911366 | 0.77 | GPR119 (0.39) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL12593934 | 0.76 | NR1H2 (0.41) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL20033881 | 0.76 | BCHE (0.38) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL1018306 | 0.76 | BCHE (0.38) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL28581988 | 0.76 | BCHE (0.38) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL19638080 | 0.75 | GPR119 (0.38) | BCHEGPR119MEN1KMT2ABUB1 | |
| SCHEMBL29288132 | 0.75 | ALDH1A1 (0.42) | BCHEGPR119MEN1KMT2ABUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| EP-3962915-B1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2024-09-04 | — | — | EP | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2022-06-16 | — | — | US | disclosed |
| EP-3962915-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020221380-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2020-11-05 | — | — | WO | disclosed |
| CN-103087078-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2486039-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1856498-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | BCHE 1887/4885GPR119 627/4885MEN1 4324/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | BCHE 2952/4885GPR119 1642/4885MEN1 2198/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | BCHE 3667/4885GPR119 2320/4885MEN1 2197/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | BCHE 3667/4885GPR119 2320/4885MEN1 2197/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | BCHE 3667/4885GPR119 2320/4885MEN1 2197/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | BCHE 3667/4885GPR119 2320/4885MEN1 2197/4885 |
| US-20220185822-A1 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR | NR1I2, NR1H2, NR1H4 | BCHE 1775/4885GPR119 31/4885MEN1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.